Skip to content

Secondary Prophylaxis Of Gastric Variceal Bleed:endoscopic cyanoacrylate injection with or without clip-assisted

Evaluation of the safety and efficacy of endoscopic tissue glue injection versus clip-assisted tissue glue injection in the treatment of fundic varices bleeding: a prospective, multicenter, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021077
Enrollment
Unknown
Registered
2019-01-27
Start date
2019-03-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Varices

Interventions

Contral group:Gastric Tissue Glue Injection
Intervention group:Clip-Assisted Gastric Tissue Glue Injection

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Those with a diagnosis of cirrhosis, including a pathologically confirmed diagnosis or clinical and imaging confirmation; 2.Gastroscopic confirmation of fundal varices (GOV type 2 or IGV type 1) requiring endoscopic treatment ; 3.The presence of a gastro-renal shunt was confirmed by imaging (enhanced CT/MRI); 4.Between =18 and =80 years of age Obtaining informed consent from subjects

Exclusion criteria

Exclusion criteria: 1.Contraindications to endoscopic tissue glue injection alone and titanium clip-assisted tissue glue injection; 2.Regional (left-sided/pancreaticogenic) portal hypertension; 3.Complete portal vein thrombosis or portal spongiform degeneration; 4.TBIL>85umol/L(5mg/dL); 5.Uncontrolled infections (e.g., spontaneous peritonitis, urinary tract infections, lung infections, etc.); 6.History of prior TIPS or surgical bypass; 7.Imaging or pathologically confirmed malignancy including hepatocellular carcinoma (beyond Milan criteria); 8.Severe dysfunction of other organs, such as end-stage renal disease under renal replacement therapy, cardiopulmonary failure, pulmonary hypertension, etc; 9.Pregnant or lactating women; 10. Those who, in the opinion of the researcher, are not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Bleeding rate;Ectopic embolism rate;

Secondary

MeasureTime frame
Survival rate;Incidence of hepatic encephalopathy;

Countries

China

Contacts

Public ContactChunqing Zhang

Shandong Provincial Hospital

zhangchunqing_sdu@163.com+86 135 8318 8661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026